Regulatory Approval for Icosapent Ethyl Soft Capsules Achieved with Kangchuanji's Support
According to the drug approval information released by NMPA, our partner has obtained the "Drug Registration Certificate" from the National Medical Products Administration for its Icosapent Ethyl Soft Capsules (0.5 g and 1.0 g), granting marketing authorization. Kangchuanji provided R&D support for this product.
2025-06-09
Quality is the lifeline of an enterprise – its core and soul.
Quality is the lifeline of an enterprise – its core and soul. To further standardize our R&D processes, effectively manage risks, and establish standardized operations and management practices, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. passed the ISO 9001 Quality Management System (CNAS) certification in January 2025.
2025-01-26
On July 18-19, the 88th Pharmaceutical QianTuHui Conference & National New Drug R&D and Investment M&A Summit was held at Nanjing Fengda International Hotel. Kangchuanji was invited to attend and set up a booth (Booth No. B02).
2024-07-21
According to the drug approval information released by NMPA, the Co-Trimoxazole Injection (specification: 5ml containing sulfamethoxazole 0.4g and trimethoprim 80mg) manufactured by Nanjing Jinling Pharmaceutical Factory of Jinling Pharmaceutical Co., Ltd. has passed the national generic drug quality and efficacy consistency evaluation (referred to as "consistency evaluation"), becoming the first manufacturer in China to have this intravenous formulation approved through the consistency evaluation. Kangchuanji provided R&D-related services for this product.
2024-08-21
According to the drug approval information released by NMPA, Guangzhou Yipinhong Pharmaceutical Co., Ltd. has obtained approval for its Olmesartan Medoxomil Orally Disintegrating Tablets. This product is the first generic version and the first to pass consistency evaluation in China. Kangchuanji provided services for this product.
2024-08-19